BBI Life Sciences Stages $37 Million IPO in Hong Kong

BBI Life Sciences, a Shanghai-based lab services company, has completed a US$37.4 million IPO in Hong Kong. BBI provides DNA synthesis products, genetic engineering services, life sciences research consumables and protein/antibody services to researchers in China, the US and Europe. BBI claims a 17.4% share of China's DNA synthesis market, making it the largest company in that field. Qiming Ventures was an early investor in BBI. More details.... Stock Symbol: (HK: 1035) Share this with colleagues: // //